NDT Pharmaceuticals(NDTP)
$0.06+0.01 (+12.24%)
NDTP
NDT Pharmaceuticals financials statements
$0.06
At close:+0.01 (+12.24%)
NDT Pharmaceuticals (NDTP) Ratios
11 Followers
NDT Pharmaceuticals Ratios
NDTP's free cash flow for Q2 2026 was $-469.81K. For the 2026 fiscal year, NDTP's free cash flow was increased by $4.00 and operating cash flow was $-469.81K. See a summary of the company’s cash flow.
| Ratios | Dec 24 | Dec 23 |
|---|---|---|
| Liquidity Ratios | ||
| Current Ratio | 0.00 | 0.02 |
| Quick Ratio | 0.00 | 0.02 |
| Cash Ratio | 0.00 | 0.02 |
| Solvency Ratio | 0.00 | 2.13 |
| Operating Cash Flow Ratio | 0.00 | -0.42 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 |
| Net Current Asset Value | $ 0.00 | $ -41.15K |
| Leverage Ratios | ||
| Debt-to-Assets Ratio | 0.00 | 0.00 |
| Debt-to-Equity Ratio | 0.00 | 0.00 |
| Debt-to-Capital Ratio | 0.00 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 |
| Financial Leverage Ratio | 0.00 | 1.41 |
| Debt Service Coverage Ratio | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 |
| Interest Debt Per Share | 0.00 | 0.00 |
| Net Debt to EBITDA | 0.00 | -0.01 |
| Profitability Margins | ||
| Gross Profit Margin | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% |
| EBT Per EBIT | 100.00% | 314.00% |
| Return on Assets (ROA) | 0.00% | -55.28% |
| Return on Equity (ROE) | 0.00% | -78.12% |
| Return on Capital Employed (ROCE) | 0.00% | -24.88% |
| Return on Invested Capital (ROIC) | 0.00% | -24.88% |
| Return on Tangible Assets | 0.00% | -55.28% |
| Earnings Yield | -0.20% | -0.81% |
| Efficiency Ratios | ||
| Receivables Turnover | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 |
| Cash Flow Ratios | ||
| Operating Cash Flow Per Share | 0.00 | -0.00 |
| Free Cash Flow Per Share | 0.00 | -0.00 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | -5921.00 |
| Capital Expenditure Coverage Ratio | 0.00 | -5921.00 |
| Operating Cash Flow Coverage Ratio | 0.00 | 0.00 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 |
| Free Cash Flow Yield | 0.00% | -0.18% |
| Valuation Ratios | ||
| Price-to-Earnings (P/E) Ratio | -530.00 | -124.00 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 0.00 | 96.87 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 0.00 | -551.82 |
| Price-to-Operating Cash Flow Ratio | 0.00 | -551.72 |
| Price-to-Earnings Growth (PEG) Ratio | 6.63 | 0.00 |
| Enterprise Value Multiple | 0.00 | 110.27 |
| Enterprise Value | 0 | 9.80M |
| EV to EBITDA | 0.00 | 110.27 |
| EV to Sales | 0.00 | 0.00 |
| EV to Free Cash Flow | 0.00 | -551.78 |
| EV to Operating Cash Flow | 0.00 | -551.69 |
| Tangible Book Value Per Share | 0.00 | 0.00 |
| Shareholders’ Equity Per Share | 0.00 | 0.00 |
| Tax and Other Ratios | ||
| Effective Tax Rate | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 |
| Net Income Per Share | -0.00 | -0.00 |
| Tax Burden | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 |
| Income Quality | 0.00 | 0.22 |
Currency in USD
